Dashboard
Manage Tickers

HRMY


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
09/12/2024 10:37:52

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

neurology-focused-harmony-biosciences-gains-confidence-with-wakix-sales-surge-strategic-pipeline-expansion-bullish-analyst-says
Neurology-Focused Harmony Biosciences Gain...
09/10/2024 18:56:30

UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's pot...

unveiling-6-analyst-insights-on-harmony-biosciences
Unveiling 6 Analyst Insights On Harmony Bi...
09/10/2024 14:01:22

ubs-initiates-coverage-on-harmony-biosciences-with-buy-rating-announces-price-target-of-56
UBS Initiates Coverage On Harmony Bioscien...
09/10/2024 12:50:56

UBS analyst Ashwani Verma initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Targ...

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
08/08/2024 10:57:47

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

analyst-expectations-for-harmony-biosciencess-future
Analyst Expectations For Harmony Bioscienc...
08/06/2024 20:00:57

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
08/06/2024 18:09:24

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

harmony-biosciences-says-on-track-to-submit-supplemental-new-drug-application-for-pitolisant-in-idiopathic-hypersomnia-in-q4-2024
Harmony Biosciences Says On Track To Submi...
08/06/2024 11:58:15

harmony-biosciences-reiterates-2024-net-product-revenue-guidance-of-700m---720m-est-710288m
Harmony Biosciences Reiterates 2024 Net Pr...
08/06/2024 11:57:31

As of June 30, 2024, Harmony had cash, cash equivalents and investments of $434.1 million, compared to $425.6 million as of Dec...

harmony-biosciences-q2-2024-adj-eps-105-beats-006-estimate-sales-172814m-miss-173098m-estimate
Harmony Biosciences Q2 2024 Adj. EPS $1.05...
08/06/2024 11:46:16

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $...

fda-confirms-favorable-benefit-risk-profile-of-wakix-harmony-biosciences-plans-to-launch-at-least-one-new-product-or-indication-annually-over-next-five-years-denial-of-citizen-petition-confirms-wakixs-safety-and-efficacy-for-eds-and-cataplexy-in-adults-with-narcolepsy
FDA Confirms Favorable Benefit-Risk Profil...
06/25/2024 12:07:04

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
06/25/2024 09:30:27

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
06/24/2024 17:01:55

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

harmony-biosciences-announces-fda-approval-of-supplemental-new-drug-application-for-wakix
Harmony Biosciences Announces FDA Approval...
06/24/2024 11:05:13

a-glimpse-into-the-expert-outlook-on-harmony-biosciences-through-7-analysts
A Glimpse Into The Expert Outlook On Harmo...
06/21/2024 17:00:34

citigroup-initiates-coverage-on-harmony-biosciences-with-buy-rating-announces-price-target-of-48
Citigroup Initiates Coverage On Harmony Bi...
06/21/2024 14:27:05

Citigroup analyst David Hoang initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price ...

harmony-biosciences-reports-data-for-pitolisant-in-the-treatment-of-excessive-daytime-sleepiness-and-fatigue-in-myotonic-dystrophy-type-1-the-primary-efficacy-endpoint-was-the-change-from-baseline-to-week-11-in-daytime-sleepiness-scale-score-secondary-efficacy-endpoints-was-also-greater-for-pitolisant-versus-placebo
Harmony Biosciences Reports Data For Pitol...
06/05/2024 12:26:09

Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excess...

needham-maintains-buy-on-harmony-biosciences-raises-price-target-to-52
Needham Maintains Buy on Harmony Bioscienc...
05/01/2024 09:34:56

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

harmony-biosciences-expands-it-cns-focused-pipeline-with-epilepsy-candidate-q1-earnings-beat-street-view
Harmony Biosciences Expands It CNS-Focused...
04/30/2024 15:44:54

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epil...

key-takeaways-from-harmony-biosciences-analyst-ratings
Key Takeaways From Harmony Biosciences Ana...
04/30/2024 13:00:33

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION